Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-20-122981
Filing Date
2020-11-09
Accepted
2020-11-09 14:39:56
Documents
93
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q casi-20200930x10q.htm   iXBRL 10-Q 1757931
2 EXHIBIT 10.1 casi-20200930xex10d1.htm EX-10.1 146555
3 EXHIBIT 10.2 casi-20200930xex10d2.htm EX-10.2 141906
4 EXHIBIT 31.1 casi-20200930xex31d1.htm EX-31.1 12459
5 EXHIBIT 31.2 casi-20200930xex31d2.htm EX-31.2 12792
6 EXHIBIT 32.1 casi-20200930xex32d1.htm EX-32.1 6456
7 EXHIBIT 32.2 casi-20200930xex32d2.htm EX-32.2 6511
  Complete submission text file 0001104659-20-122981.txt   7564386

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA casi-20200930.xsd EX-101.SCH 69602
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE casi-20200930_cal.xml EX-101.CAL 60477
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE casi-20200930_def.xml EX-101.DEF 167219
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20200930_lab.xml EX-101.LAB 448706
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20200930_pre.xml EX-101.PRE 392721
13 EXTRACTED XBRL INSTANCE DOCUMENT casi-20200930x10q_htm.xml XML 1199970
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

EIN.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-20713 | Film No.: 201297207
SIC: 2836 Biological Products, (No Diagnostic Substances)